ClinicalTrials.gg

TargetBeta

CRBN

cereblon · also MRT2, MRT2A

6 programs in company-led studies act on CRBN, from 2 companies: 2 in phase 3, 2 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
LenalidomideruleBristol-Myers Squibbphase 410918 runningCUL4A, DDB1, RBX1ChEMBL
pomalidomideruleBristol-Myers Squibbphase 45112 runningCUL4A, DDB1, RBX1ChEMBL
golcadomideBristol-Myers Squibbphase 3117 running–a judged reading
mezigdomideBristol-Myers Squibbphase 3124 running–a judged reading
Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506Bristol-Myers Squibbphase 111 running–a judged reading
HRS-3738Jiangsu HengRui Medicinephase 111 running–the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.